Estuary Biotherapeutics
PrivateLast Round
Series A
Oct 16, 2026
Total Funding Raised
$103M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Estuary Biotherapeutics is a biotechnology company developing gene therapies for patients with serious kidney diseases, specifically autosomal dominant polycystic kidney disease (ADPKD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Estuary Biotherapeutics Comparables
Compare Estuary Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Renasant Bio | 85% | |
| Purespring Therapeutics | 83% | |
| Regulus Therapeutics Inc. | 78% |
Estuary Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 16, 2026 |
Estuary Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| GV | Series A, Seed |
| 4BIO Capital | Series A, Seed |
| Deep Track Capital | Series A |
| Pivotal bioVenture Partners | Series A |
| UPMC Enterprises | Series A |
| National Kidney Foundation | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 16, 2026
$93M round led by RA Capital Management.
Recent news
Latest coverage and updates
- receives_financingOct 19, 2026
Estuary Biotherapeutics, Inc. receives $10M in Seed financing co-led by 4BIO Capital and GV Funding, which also participate in its Series A.
- is_developingOct 19, 2026
Estuary Biotherapeutics, Inc. hopes to advance its lead programs, EST-201 and EST-101, toward clinical proof of concept for autosomal dominant polycystic kidney disease while further developing its kidney-targeting platform on Oct 19th '26.
Estuary Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Estuary Biotherapeutics's valuation, stock price, and market status.
Is Estuary Biotherapeutics a public or private company?
Estuary Biotherapeutics is a private company.
What is the current stock price of Estuary Biotherapeutics?
Estuary Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Estuary Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Estuary Biotherapeutics worth (valuation)?
Valuation information for Estuary Biotherapeutics is not publicly available.
Can I buy Estuary Biotherapeutics stock?
Estuary Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Estuary Biotherapeutics's last funding round?
Estuary Biotherapeutics's most recent funding round was Series A on October 16, 2026.
Who are the main investors in Estuary Biotherapeutics?
Key investors in Estuary Biotherapeutics include RA Capital Management, GV, 4BIO Capital.
Will Estuary Biotherapeutics IPO soon?
No public IPO plans have been announced for Estuary Biotherapeutics.
How can I track Estuary Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Estuary Biotherapeutics's shares on secondary markets.